CAMBRIDGE, Mass., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that Kyle Kuvalanka, chief business officer, will present a company overview at the JMP Securities Life Sciences Private Company Conference on Friday, October 17, 2014 at 9:00 a.m. EDT at Le Parker Meridien Hotel in New York, NY.
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint Medicines has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint Medicines to rapidly discover potent and highly selective drugs against clear drivers of diseases. Founded in 2011, Blueprint Medicines is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit www.blueprintmedicines.com.
CONTACT: Investor Relations: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Relations: David Polk Chandler Chicco Companies 310 309 1029 dpolk@chandlerchiccocompanies.com Help employers find you! Check out all the jobs and post your resume.
